Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak

AI-generated analysis

🏥 Regeneron Pharmaceuticals announced that its antibody therapy, maftivimab, was recommended by the WHO's Therapeutics Advisory Group for evaluation in clinical trials against Bundibugyo ebolavirus.

🌍 This recommendation comes following the WHO's declaration of a public health emergency regarding the Ebola outbreak in Uganda and the Democratic Republic of the Congo.

💉 Maftivimab is identified as the most potent neutralizing antibody within Regeneron's Inmazeb® product and has shown broad activity against multiple Ebola species in vitro.

📉 Canaccord Genuity lowered its price target on Regeneron stock from $1,057 to $875 while maintaining a Buy rating.

⚠️ The analyst firm updated its model after Regeneron's Phase 3 study of fianlimab+cemiplimab failed to meet the primary endpoint of progression-free survival.

🧬 Regeneron develops and commercializes therapies for various diseases, including cancer, eye disorders, and allergic conditions.

📰 The article includes promotional content suggesting AI stocks may offer higher returns than Regeneron in the short term.

🔗 Readers are directed to additional reports on high-upside healthcare stocks and market rotation strategies.

Bullish Signals
  • Regeneron's maftivimab has been recommended by the World Health Organization's Therapeutics Advisory Group for prioritization in clinical trials against Bundibugyo ebolavirus.
  • Maftivimab is identified as the most potent neutralizing antibody included in Inmazeb, demonstrating broad activity against multiple Ebola species.
  • The positive development coincides with the WHO declaring the current Ebola outbreak a public health emergency of international concern, highlighting the therapy's relevance.
  • Analysts maintain a Buy rating on Regeneron shares despite recent trial results, indicating continued confidence in the company's long-term prospects.
Risk Factors
  • Analyst firm Canaccord Genuity lowered its price target on Regeneron shares from $1,057 to $875 on May 19.
  • A Phase 3 study comparing fianlimab and cemiplimab against pembrolizumab failed to achieve statistical significance on the primary endpoint of progression-free survival.
  • Regeneron described the outcome of the failed Phase 3 study as surprising and disappointing.
Full Analysis
Regeneron Pharmaceuticals announced on May 28 that its antibody therapy, maftivimab, has been recommended by the World Health Organization's Therapeutics Advisory Group for prioritization in clinical trials investigating treatments for Bundibugyo ebolavirus. This recommendation follows a WHO declaration regarding an outbreak of Ebola caused by the Bundibugyo virus in Uganda and the Democratic Republic of Congo, which was designated a public health emergency of international concern. Maftivimab is identified as the most potent neutralizing antibody within Regeneron's Inmazeb product and has demonstrated broad activity against multiple Ebola species in vitro. In separate financial news, analyst firm Canaccord Genuity lowered its price target on Regeneron shares to $875 from $1,057 on May 19, though it maintained a Buy rating. The adjustment reflects an updated model following the conclusion of a Phase 3 study comparing fianlimab and cemiplimab against pembrolizumab, which failed to achieve statistical significance on the primary endpoint of progression-free survival. Regeneron describes this outcome as surprising and disappointing, noting that the company continues to develop therapies for various diseases including cancer, eye disorders, and allergic conditions.